GENE ONLINE|News &
Opinion
Blog

2022-01-10| Asia-PacificIPO

Vertex Is Looking to Become Singapore’s First SPAC

by Joy Lin
Share To

Last September, the Singapore Exchange (SGX) changed its framework to allow special purpose acquisition companies (SPACs) to list. Now, Vertex Technology Acquisition Company (VTAC) is set to become the first SPAC to list in the country, after the company lodged a preliminary prospectus with the Monetary Authority of Singapore (MAS).

A subsidiary of Singapore venture capital firm Vertex Holdings, VTAC is seeking to raise S$200 million (nearly $150 million), by selling 40 million units at an offered price of S$5.00 each.  

VTAC announced that 13 cornerstone investors, including UBS Asset Management, Venezio Investments, and Fullerton Fund Management Company, have subscribed to 65% of the shares offered, accounting for 22.2 million units that will raise S$111 million. 

Its sponsor Vertex Venture Holdings have also booked $30 million for the fundraising through its subsidiary Vertex Co-Investment Fund. 

When it lists at the end of the month, VTAC will have 24 months to complete a reverse merger. While VTAC did not disclose any specific combination targets in its prospectus, its focus will be on biotech and digital healthcare, and technologies related to artificial intelligence, cyber security and enterprise, consumer Internet, finance, autonomous driving, and new energy vehicles.

SPACs in Asia 

 

SPAC listings may become more common in Asia as countries change their frameworks. Hong Kong recently changed its rules to allow SPACs to begin listing this January. Elsewhere, SPACs have already been greenlighted in Korea and Malaysia, and are given 36 months to complete an acquisition compared to the usual 24.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023-11-20
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top